医疗器械风险分担协议:捷克的一个基于利益相关者的定性研究
Petra Hospodková1, Vladimír Rogalewicz1
1Department of Biomedical Technology, Faculty of Biomedical Engineering, Czech Technical University in Prague, Kladno, Czechia.
Frontiers in public health
|September 19, 2025
概括
基于结果的医疗器械风险分担协议面临监管,数据基础设施和机构意愿方面的障碍. 需要试点计划和对现实世界的证据进行投资,以实现更广泛的采用.
科学领域:
- 卫生经济学 卫生经济学
- 医疗设备创新 医疗设备创新
- 退款政策 退款政策
背景情况:
- 创新医疗技术带来了不断上升的成本和不确定的临床价值.
- 基于结果的风险分担协议正在获得引力,特别是在药品行业.
- 在医疗器械领域的应用是有限的和未被充分探索的.
研究的目的:
- 检查利益相关者对医疗器械基于结果的协议的观点.
- 确定在医疗器械领域实施这些协议的关键障碍.
主要方法:
- 定性研究设计. 定性研究设计.
- 与各种利益相关者 (付款人,提供者,监管机构,行业) 进行了16次半结构化访谈.
- 使用感应编码对采访成绩单进行主题分析.
主要成果:
- 确定的主要障碍:监管/法律不确定性,现实世界结果测量基础设施薄弱,以及对共享风险的机构不情愿.
- 利益相关者认识到基于结果的协议的概念上的好处.
- 对高成本地区的小规模试点计划表示支持.
结论:
- 更广泛的采用需要监管和机构的发展.
- 对数据基础设施进行有针对性的投资至关重要,特别是对现实世界的证据进行大数据分析.
- 这将支持医疗器械的可持续,透明和基于证据的报销决策.
相关概念视频
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
407
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
407
Bioequivalence studies: Biowaivers
229
Body:In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
229
Drug Products: Biologics, Biosimilars and Interchangeables
235
Body:Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
235


